Digilab Acquires BioVisioN to Develop Disease-Management Products

Digilab announced this week that it has acquired peptide-profiler BioVisioN.

"We plan to integrate proprietary Digilab tools into research processes and ultimately disease management systems," said Digilab President David Giddings in a statement.

Financial details were not released.

BioVisioN patented the Peptidomics technology and Differential Peptide Display software for peptide biomarker discovery. It is based in Hannover, Germany.